Aveanna Healthcare (AVAH) Is Up 64.2% After Raising 2025 Revenue Outlook Post-Thrive Acquisition – Has the Long-Term Narrative Shifted?

• Aveanna Healthcare Holdings recently reported strong second quarter results, showing significant year-over-year growth in revenue and net income, and updated its 2025 guidance to project annual revenue of over US$2.3 billion following the completion of its acquisition of Thrive Skilled Pediatric Care.
• Despite recording a goodwill and asset impairment loss of US$153,000 this quarter, up from US$80,000 last year, the company’s operational momentum, boosted by M&A activity and rising patient demand, led management to offer a more positive outlook for the full year.
• We'll explore how Aveanna's upward revision of its 2025 revenue guidance following the Thrive acquisition could impact its long-term investment outlook.

AI is about to change healthcare. These 24 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

Aveanna Healthcare Holdings Investment Narrative Recap

To be an Aveanna Healthcare Holdings shareholder, you need to believe the company's ability to scale in-home care amid strong industry demand can outpace risks from reimbursement pressures and wage inflation. The recent earnings beat and raised 2025 revenue guidance reinforce patient volume growth as the main near-term catalyst, while the biggest risk, persistent margin pressure from labor and regulatory headwinds, remains ongoing and largely unaltered by the latest results.

Of the company’s recent news, the increased full-year revenue guidance above US$2.3 billion following the Thrive acquisition stands out. This directly supports the case for scale-driven growth but leaves questions about how Aveanna will navigate external funding changes and operating costs as it expands.

By contrast, investors should be mindful of continuing regulatory risk and shifts in Medicaid or Medicare funding that could...

Read the full narrative on Aveanna Healthcare Holdings (it's free!)

Aveanna Healthcare Holdings' outlook anticipates $2.4 billion in revenue and $75.4 million in earnings by 2028. This scenario requires a 3.5% annual revenue growth rate and an earnings increase of $56.8 million from current earnings of $18.6 million.

Uncover how Aveanna Healthcare Holdings' forecasts yield a $6.07 fair value, in line with its current price.

Exploring Other Perspectives

Four private investors in the Simply Wall St Community rated Aveanna’s fair value between US$4.29 and US$12.40 per share. Despite confidence in revenue momentum, ongoing exposure to Medicaid and Medicare funding pressures could significantly influence financial outcomes, so explore several viewpoints before forming your own opinion.

Explore 4 other fair value estimates on Aveanna Healthcare Holdings - why the stock might be worth over 2x more than the current price!

Build Your Own Aveanna Healthcare Holdings Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Aveanna Healthcare Holdings research is our analysis highlighting 2 key rewards and 5 important warning signs that could impact your investment decision.
• Our free Aveanna Healthcare Holdings research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Aveanna Healthcare Holdings' overall financial health at a glance.

Contemplating Other Strategies?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

• Outshine the giants: these 20 early-stage AI stocks could fund your retirement.
• This technology could replace computers: discover 26 stocks that are working to make quantum computing a reality.
• Uncover the next big thing with financially sound penny stocks that balance risk and reward.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com